Leveraging nature’s nanocarriers: Translating insights from extracellular vesicles to biomimetic synthetic vesicles for biomedical applications
Science Advances,
Год журнала:
2025,
Номер
11(9)
Опубликована: Фев. 26, 2025
Naturally
occurring
extracellular
vesicles
(EVs)
and
synthetic
nanoparticles
like
liposomes
have
revolutionized
precision
diagnostics
medicine.
EVs
excel
in
biocompatibility
cell
targeting,
while
offer
enhanced
drug
loading
capacity
scalability.
The
clinical
translation
of
is
hindered
by
challenges
including
low
yield
heterogeneity,
whereas
face
rapid
immune
clearance
limited
targeting
efficiency.
To
bridge
these
gaps,
biomimetic
(SVs)
emerged
as
innovative
platforms,
combining
the
advantageous
properties
liposomes.
This
review
emphasizes
critical
aspects
EV
biology,
such
mechanisms
EV-cell
interaction
source-dependent
functionalities
modulation,
tissue
regeneration,
informing
SV
engineering.
We
reviewed
a
broad
array
SVs,
with
focus
on
lipid
bilayered
functionalized
proteins.
These
include
cell-derived
nanovesicles,
protein-functionalized
liposomes,
hybrid
vesicles.
By
addressing
current
highlighting
opportunities,
this
aims
to
advance
SVs
for
transformative
biomedical
applications.
Язык: Английский
Biomimetic Nanoparticles for Basic Drug Delivery
Pharmaceutics,
Год журнала:
2024,
Номер
16(10), С. 1306 - 1306
Опубликована: Окт. 7, 2024
Biomimetic
nanoparticles
(BMNPs)
are
innovative
nanovehicles
that
replicate
the
properties
of
naturally
occurring
extracellular
vesicles,
facilitating
highly
efficient
drug
delivery
across
biological
barriers
to
target
organs
and
tissues
while
ensuring
maximal
biocompatibility
minimal-to-no
toxicity.
BMNPs
can
be
utilized
for
therapeutic
payloads
imparting
novel
other
nanotechnologies
based
on
organic
inorganic
materials.
The
application
specifically
modified
membranes
coating
has
potential
enhance
their
efficacy
biocompatibility,
presenting
a
promising
pathway
advancement
technologies.
This
manuscript
is
grounded
in
fundamentals
biomimetic
technologies,
offering
comprehensive
overview
analytical
perspective
preparation
functionalization
BMNPs,
which
include
cell
membrane-coated
(CMCNPs),
artificial
cell-derived
vesicles
(ACDVs),
fully
synthetic
(fSVs).
review
examines
both
"top-down"
"bottom-up"
approaches
nanoparticle
preparation,
with
particular
focus
techniques
such
as
membrane
coating,
cargo
loading,
microfluidic
fabrication.
Additionally,
it
addresses
technological
challenges
solutions
associated
large-scale
production
clinical
related
Язык: Английский
Optimizing mRNA delivery: A microfluidic exploration of DOTMA vs. DOTAP lipid nanoparticles for GFP expression on human PBMCs and THP-1 cell line
International Journal of Pharmaceutics,
Год журнала:
2025,
Номер
672, С. 125324 - 125324
Опубликована: Фев. 7, 2025
Язык: Английский
Biomaterial design for proactive modulation of the complement system
Nature Reviews Bioengineering,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 13, 2025
Язык: Английский
Danicopan’s FDA approval: a breakthrough in the treatment of paroxysmal nocturnal hemoglobinuria
International Journal of Surgery Global Health,
Год журнала:
2025,
Номер
8(2)
Опубликована: Фев. 27, 2025
The
FDA’s
approval
of
Danicopan
(Vodeya)
on
1
April
2024,
represents
a
significant
advancement
in
the
treatment
Paroxysmal
Nocturnal
Hemoglobinuria
(PNH).
As
first
oral
serine
protease
factor
D
inhibitor,
complements
existing
C5
inhibitors
by
addressing
both
intravascular
and
extravascular
hemolysis.
In
phase
3
ALPHA
trial,
as
an
add-on
therapy
to
ravulizumab
or
eculizumab
significantly
improved
hemoglobin
levels,
with
least
squares
mean
difference
2.44
g/dL
compared
placebo
(
P
<
0.0001).
Key
advancements
include
its
ability
reduce
transfusion
dependency,
improve
patient
quality
life,
convenient
administration
intravenous
therapies.
Potential
side
effects
severe
headache,
fever,
blurred
tunnel
vision,
sudden
dizziness,
increased
risk
infections
encapsulated
organisms,
along
rare
adverse
events
such
elevated
liver
enzymes
neutropenia.
Danicopan’s
fills
critical
therapeutic
gap,
offering
transformative
approach
managing
PNH.
Язык: Английский
PLA/PLGA nanocarriers fabricated by microfluidics-assisted nanoprecipitation and loaded with Rhodamine or gold can be efficiently used to track their cellular uptake and distribution
International Journal of Pharmaceutics,
Год журнала:
2024,
Номер
667, С. 124934 - 124934
Опубликована: Ноя. 10, 2024
This
study
represents
a
pioneering
investigation
into
using
microfluidic
technology
for
manufacturing
PLA
and
PLGA
nanocarriers
(NCs)
loaded
with
tracer
molecules
or
metals
through
co-precipitation
protocol
that
involves
saturating
the
water
phase.
The
effects
of
total
flow
rate
(TFR),
ratio
(FRR),
surfactant
amount,
polymer
concentration
on
particle
sizes
distributions
were
examined.
average
size
PLA-NCs
varied
from
349
±
175
nm
to
170
64
nm,
surface
charges
ranging
-13
-6
mV.
In
contrast,
PLGA-NCs
had
an
between
192
46
100
34
-23
mV
-53
Increasing
TFR
6
10
mL/min
fixed
FRR
1:1
reducing
concentrations
in
organic
phase
20
5
mg/mL
generally
resulted
smaller
NC
(monodispersed),
consistently
exhibiting
dimensions.
Under
these
specific
conditions,
Rhodamine
B
(Rhod)
gold
(Au)
successfully
loaded,
achieving
encapsulation
efficiencies
exceeding
50
%.
Electron
microscopy
analysis
confirmed
exhibited
consistent
spherical
shape
smooth
morphology.
X-ray
energy-dispersive
spectroscopy
(EDX)
revealed
uniform
distribution
within
matrix.
effectively
internalized
by
various
cell
types,
including
human
Peripheral
Blood
Mononuclear
Cells
(PBMCs),
HT-29
colon
cancer
cells,
C6
glioma
cells.
Uptake
occurred
dose-dependent
manner
sized
at
260
51
only
30
%
internalization
2
after
24
48
h.
Notably,
mean
achieved
nearly
uptake
across
all
tested
types
h,
indicating
significantly
influenced
cellular
uptake.
Язык: Английский